Archives

FDA approves CAPLYTA® (lumateperone) sNDA with robust new data supporting reduced risk of relapse in schizophrenia

B CAPLYTA® reduced relapse risk by 63 percent, with 84 percent of patients with schizophrenia relapse-free over six months Demonstrating long-term stability and a well-established… Login to continue reading Login…

Read MoreFDA approves CAPLYTA® (lumateperone) sNDA with robust new data supporting reduced risk of relapse in schizophrenia

Duck Creek Kicks Off Formation ’26 as Strong Fiscal Momentum Signals Accelerating Demand for its Intelligent Core Insurance Platform

B Company highlights double-digit SaaS growth, global expansion, and launch of its new agentic AI platform as industry leaders gather in Orlando BOSTON, April 27, 2026 /PRNewswire/ — Duck… Login to continue reading Login…

Read MoreDuck Creek Kicks Off Formation ’26 as Strong Fiscal Momentum Signals Accelerating Demand for its Intelligent Core Insurance Platform

Microsoft’s Fourth Failed Invalidation Attempt Brings Newman Infinite Touch Patent Dispute to China Supreme People’s Court

B Backed by four failed challenges and CNIPA’s recent Public Lecture presentation of its “Top 10 Case” designation, the dispute over touchscreen technology used in… Login to continue reading Login…

Read MoreMicrosoft’s Fourth Failed Invalidation Attempt Brings Newman Infinite Touch Patent Dispute to China Supreme People’s Court